Alexion Antibody Technologies, Inc. Company Profile

10:17 EDT 24th March 2018 | BioPortfolio

Alexion Antibody Technologies, Inc. (AAT) is a wholly owned subsidiary of Alexion Pharmaceuticals [ALXN]. AAT is engaged in discovering and developing a portfolio of antibody therapeutics targeting severe unmet medical needs including cancer, autoimmune disorders, and inflammation. AAT was formed in September 2000 from the merger of the discovery platform of Prolifaron, Inc. with the established antibody development capacity of Alexion Pharmaceuticals, forming a powerhouse in antibody discovery and development. Alexion is approaching full integration, from discovery through commercialization.


3985 Sorrento Valley Blvd Ste, A
San Diego
United States of America


Phone: (858) 550-3490
Fax: (858) 550-3498

News Articles [722 Associated News Articles listed on BioPortfolio]

US expands use of Alexion rare disease therapy Soliris

Alexion’s rare disease therapy Soliris can now be used in the US to treat generalised myasthenia gravis in patients who are anti-acetylcholine receptor antibody-positive, offering this group the...

Alexion Gains Access To ENHANZE Technology; Halozyme To Receive $40 Mln Payment

WASHINGTON (dpa-AFX) - Alexion Pharmaceuticals, Inc. (ALXN) and Halozyme Therapeutics, Inc. (HALO) announced a collaboration and license agreement that enables Alexion to use Halozyme's ENHANZE dr...

Alexion Pharmaceuticals Bouncing Off Lowest Closing Level In Six Months

WASHINGTON (dpa-AFX) - Shares of Alexion Pharmaceuticals (ALXN) are seeing significant strength in afternoon trading on Friday, jumping by 8.7 percent. Alexion is bouncing off its lowest closing l...

FDA Approves Alexion’s Soliris for Treatment of Generalized Myasthenia Gravis

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved Soliris® (eculizumab) as a trea...

Alexion next stop for Camilla Harder Hartvig

Following the departure of Christophe Bourdon in December, US drugmaker Alexion Pharmaceuticals has named…

Alexion earnings exceed estimates

Alexion Pharmaceuticals exceeded analysts’ expectations with its financial results for the fourth quarter…

Why Boston-Bound Alexion Could be a Compelling M&A for Larger Drugmakers

Here are the reasons that suggest that Alexion is about to shake off its doldrums and enjoy a dramatic turn in fortune.

Activist Investor Urges Alexion to Sell Itself or Else

Elliott Management has built a stake in Alexion and has urged the biopharma to do more to lift its stock price.

PubMed Articles [1164 Associated PubMed Articles listed on BioPortfolio]

Integration of Antibody Array Technology into Drug Discovery and Development.

Antibody arrays represent a high-throughput technique that enables the parallel detection of multiple proteins with minimal sample volume requirements. In recent years, antibody arrays have been widel...

Protein Arrays I: Antibody Arrays.

Antibody arrays represent one of the very early protein array systems where antibodies are used to capture and detect target proteins in a high-throughput platform. The development of high-quality ant...

Rapid preparative separation of monoclonal antibody charge variants using laterally-fed membrane chromatography.

Monoclonal antibodies undergo various forms of chemical transformation which have been shown to cause loss in efficacy and alteration in pharmacokinetic properties of these molecules. Such modified an...

Antibody Glycoengineering Strategies in Mammalian Cells.

As a key parameter impacting functional and structural heterogeneity, protein glycosylation is a critical quality attribute for antibody biotherapeutic manufacturing. The glycan patterns on recombinan...

A sensitive and robust HPLC method to quantify recombinant antibody fragments in E. coli crude cell lysate.

Clinical Trials [1852 Associated Clinical Trials listed on BioPortfolio]

Application of Monitoring and Intervention Technologies in Suboptimal Health Status

The purpose of this study is to use monitoring and intervention technologies in suboptimal health status in a general population in China and evaluate the effectiveness of these technologi...

Wheeze Detection in Adults During Dynamic Bronchial Situations Measured by PulmoTrack® 2010 With WIM-PC™ Technologies Recording

The PulmoTrack® 2010 with WIM-PC™ Technologies device, indicated for acoustic pulmonary function measurement that quantifies the presence of wheezing. This study was designed in order t...

Testing Latest Version of NidekRS3000Adv

The investigators would like to know if different imaging devices can improve the quality of images and visualization of imaged tissues. Also, the investigators would like to find out whet...

JCV Antibody Program (STRATIFY-1)

Study conducted to define the prevalence of Serum JC Antibody in relapsing MS patients receiving Tysabri or being considered for such treatment. Analytically validate the JCV antibody ass...

Expanded Access Study of Iodine-131 Anti-B1 Antibody

The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on...

Companies [1650 Associated Companies listed on BioPortfolio]

Alexion Antibody Technologies, Inc.

Alexion Antibody Technologies, Inc. (AAT) is a wholly owned subsidiary of Alexion Pharmaceuticals [ALXN]. AAT is engaged in discovering and developing a portfolio of antibody therapeutics targeting se...

Alexion Pharmaceuticals Inc.

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed ...

Alexion Pharmaceuticals Incorporated

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rar...

Antibody Solutions Inc

Antibody Solutions Inc., based in Mountain View in the San Francisco Bay Area, offers quality antibody development, antibody manufacture and immunoassay development that are optimized for your specifi...

Takeda San Francisco Inc.

Takeda San Francisco was established in November 2007 and supports Takeda's therapeutic antibody research aiming to build antibody technology platforms based on technologies such as discovery and ...

More Information about "Alexion Antibody Technologies, Inc." on BioPortfolio

We have published hundreds of Alexion Antibody Technologies, Inc. news stories on BioPortfolio along with dozens of Alexion Antibody Technologies, Inc. Clinical Trials and PubMed Articles about Alexion Antibody Technologies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alexion Antibody Technologies, Inc. Companies in our database. You can also find out about relevant Alexion Antibody Technologies, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Corporate Database Quicklinks

Searches Linking to this Company Record